source: [12.10.2007]

Slides:



Advertisements
Similar presentations
Medicines Prices and Methods of Financing in South-East Asia Indian Pharmacological Society 38 th Annual Conference, Chennai 29th December 2005 Dr K Weerasuriya,
Advertisements

MDG Target 8.E gap analysis Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical Policies, World Health Organization 27 August 2008.
Pharmaceutical Policy and Pricing: How are Countries Getting Greater Value? Commonwealth Fund/ Alliance for Health Reform Briefing on Capitol Hill Dr.
1 MDG Target 8.E gap analysis Dr Hans Hogerzeil Director, Department of Essential Medicines and Pharmaceutical Policies, World Health Organization October.
Delivering local determinations and setting sanctions Speakers: Simon Bird Deputy President The Adjudication Panel for England Mark Jones Principal Legal.
Pricing and Reimbursement Policies 27. Pricing Policies Patented Medicines Patented Medicine Prices Review Board (PMPRB) monitors and sets the price of.
GS1 standards – advantages and barriers in the produce of medicine Bratislava, 20. September 2007 Peter Vavro Logistics manager, Zentiva, a.s.
Government and Health Care Roughly 15 cents of every dollar spent in US is on health care US health care spending equaled $5841 per person in 2002 Governments.
OPTIMAL PRESENT RESOURCE EXTRACTION UNDER THE INFLUENCE OF FUTURE RISK Professor Dr Peter Lohmander SLU, Sweden,
The Korus FTA Will Lead to Higher Drug Prices in Korea
The American Problem: Health Insurance Jennifer Bernstein Michael Berry Tom Chiang Ryan Lubitz Leanne Lundby.
QUALITY, ENVIRONMENTAL AND OCCUPATIONAL HEALTH AND SAFETY POLICY.
Strengthening the Steering Role and Implementation of the Sectoral Policy in the Dominican Republic Mr. Juan Esteban Peguero Mateo Bureau of Health Planning.
Pricing and Reimbursement Policies 1. Pricing Policies Patented Medicines Maximum retail prices capped by Ministry of Economy (mainly for private sector)
Transfer Pricing Summary. Key points Parties should be acting on information regarding marginal costs and marginal benefits to the company. External markets.
Pricing Pharmaceuticals: Has Public Policy Delivered? Paul K Gorecki ESRI & TCD Irish Economic Policy Conference 2014: Economic Policy After the Bailout.
Child Care and Development Block Grant (CCDBG): Brief Introduction
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
“Generic Medicines in the Taiwanese and German Legal Systems” 03 June 2011 in Taipei, Taiwan Role of Generics in the German Health Care System Financial.
Current Approaches in European Health Care Policy What models can balance the needs of payors and industry?
1 Chapter 7 Consumer Choice and Elasticity. 2 Overview  Fundamentals of consumer choice and diminishing marginal utility  Consumer equilibrium  Income.
Audit of Public Procurement
Implementing the Reforms for Special Educational Needs and Disability Children and Families Act 2014 September 1 st 2014 What has Changed? East Sussex.
Dr Odysseas Michaelides Auditor General of the Republic June 2014 The role of the SAIs in times of economic crisis Audit Office of the Republic of Cyprus.
Student ID:MA3N0202 Name: Li-Wen Chang(Jenny) 1.  What’s the “Financial supervision mechanism”  The Financial Supervisory Commission (FSC)  Case ─
1 DRUG DATABASE AND PERFORMANCE INDICATORS FOR UTILIZATION MONITORING Authors: Pongcharoensuk P 1, Angsanant M 2, Chantrakunopars P 2, Phuthong P 1, Kongsawat.
 Both fee-for-service and managed care cover medical,surgical, and hospital expenses  Can also cover prescription drugs and dental  Both pay premiums.
The consequences of the National Health Account for Occupational Health Services evaluation in Poland ICOH, Amsterdam 2002 Izabela Rydlewska – Liszkowska.
The competition between innovative and generic pharmaceutical companies intensified in the last decades. The models created by innovative pharmaceutical.
1 ASSESSING FISCAL RISKS THROUGH LONG-TERM BUDGET PROJECTIONS Paal Ulla Budgeting & Public Expenditures Division Public Governance & Territorial Development.
TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.
HTA and Health Care Decisions in Slovakia. PharmDr. Martin Višňanský, MBA, PhD. President - ISPOR Local Chapter, Slovakia Slovak Agency for Health Technology.
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
1. General characteristics of the changes 2. Legal and macro-economic aspects of changes; procedural issues 3. Changes in the “incomes” section of the.
Spatial Conflicts in New Zealand Fisheries: The Rights of Fishers and Protection of the Marine Environment Randall Bess, Ramana Rallapudi Marine Policy.
Regulatory Institutions in Turkey. Regulatory Institutions Central Bank of Turkey Banking Supervision and Regulatory Institutions Capital Markets Board.
Drug Policy Experience of Visegrad Group countries, Warszava Oct 29-30, 2007 System of counting of reimbursement costs in the Czech Republic Tomas Sechser.
Science, research and development European Commission IDARI Project Meeting Tartu, June 2005 Martin Greimel Scientific Officer Directorate-E ‘Biotechnology,
PUBLIC PROCUREMENT SYSTEM IN TAJIKISTAN RAVSHAN KARIMOV AGENCY FOR PUBLIC PROCUREMENT UNDER THE GOVERNMENT OF THE REPUBLIC OF TAJIKISTAN.
1 FIRST STAGE OF THE HIGHER EDUCATION REFORM IN CROATIA – TASKS OF AUTHORISED BODIES.
HTA in Poland Wojciech Matusewicz, Ph.D., M.D. – Director Iga Lipska, M.D. – Head of HTA Department Agency for Health Technology Assessment in Poland AHTAPol.
1 Need for co-operation of Visegrad - group countries and ways of its organization Warsaw, Oct , 2007.
Reimbursement system in Slovakia Michaela Gajdošová Gabriela Kliešková Ministry of Health Slovakia.
Drug Policy Experience of Visegrad Group countries, Warszava Oct 29-30, 2007 Monitoring of doctor´s prescription in the Czech Republic Tomas Sechser Daniela.
Trans-boundary EIA in the Slovak Republic History 18 November 1999 Ratification of ESPOO Convention by the Slovak Republic 17 February 2000 ESPOO Convention.
1 Access to financial services in South Africa FSCC presentation to Portfolio Committee on Finance National Assembly 26 August 2005.
1 Vision: To be an agency producing outputs that contribute to optimal efficiency of the Indonesian Universal Health Coverage (UHC) Mission: To ensure.
Crime and Drugs Christopher Campbell. Different Views of Legalization  Liberty: An argument for legalization  Paternalism: An argument against legalization.
South Africa’s Acceptance of the Protocol Amending the TRIPS Agreement Xolelwa Mlumbi- Peter DDG: ITED 24 November 2015.
340B In New Mexico Senator Dede Feldman New Mexico State Legislature 8/5/05.
Meeting of the Policy Group on Statistical Cooperation COORDINATION OF THE NATIONAL STATISTICAL SYSTEM OF THE REPUBLIC OF MACEDONIA Point 9 of the Agenda.
Problems Due Thursday, September 27. A Simple Model Goods Where: M = Medical care w/ price p m z = all else w/ price 1 r = insurer’s share of payment.
1 PRESENTATION TO PC ON HUMAN SETTLEMENTS ON LEGISLATIVE PROCESS 26 AUGUST 2014.
An Employer Perspective Moosehead Breweries Ltd. Mike Lee Vice President – Human Resources.
Monopoly 15. Monopoly A firm is considered a monopoly if... it is the sole seller of its product. it is the sole seller of its product. its product does.
5-1 © The McGraw-Hill Companies, Inc., 2009 McGraw-Hill/Irwin LO  Cost-Benefit Principle at work  Do something if the marginal benefits are at.
RECENT CORPORATE GOVERNANCE REFORM IN RM Prof. Tito Belicanec, PH.D.
Missing Trader Fraud - Germany
School Site Councils & Site Governance Teams
Implementation of the Sustainable Development Goals (SDG) in the Republic of Uzbekistan Geneva, April 12, 2017.
BUSINESS HIGH SCHOOL-ECONOMICS
Composition of the National Advisory Panel
Vision, Mission, and Goals
البيئة السياسية للإدارة الدولية
SLOVAKIA : OLD-AGE PENSION SAVINGS („II. PILLAR“)
First International Medical Device Compliance Congress
Joint inspections and cooperation with other institutions in Bulgaria
Realizing effective health technology assessment for the SA healthcare environment Praneet Valodia The BHF Southern African Conference July’07.
COOPERATION WITHIN UNDERTAKINGS
Project DIRECT Final Summary
Presentation transcript:

source: [ ]

◘ In June 2003, legal amendments dramatically changed the drug categorization system. The number of ATC groups in which at least one drug has to be fully reimbursed by law decreased to 122.

◘ The composition of the categorization committee was changed, with greater participation of health insurance companies΄ representatives and a higher emphasis on cost-effectiveness analysis.

◘ Generic substitution, maximum prices, price monitoring in the reference countries are implemented within the Slovak’s drug policy and introduction of a degressive margin is prepared.

Problems: The cost – effectiveness threshold is not agreed. ATC group NamedosisPrice per day € A02BC01Omeprazol 10 mg 0.52 A02BC01Omeprazol 20 mg 0.12 A02BC02Pantoprazol 1.45 A02BC02Pantoprazol 40 mg 1.27 A02BC05Ezomeprazol 20 mg 0.86 A02BC05Ezomeprazol 40 mg % 1208 % an example:

The majority of HTA are transfrered. however Not all participated parties within reimbursement process determine 14 transferability factors: ◘ To which content it is relevant for the investigated technology ◘ How much it corresponds between the study and country’s decision ◘ The likely effect of the transferability factor on the cost-effectiveness ratio

◘ Inconsistent reimbursement decisions can be consider as one of the main reasons for the accumulation of expenditures on drugs within the Slovak Republic. ◘ The principe “VALUE FOR MONEY” as a reasonable criterion for making resource allocation decision within the health care system should be implemented more deeply.